Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhifeng Cheng

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Nature Communications|May 8, 2026
Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2)Weiping Jia, Fei Gao, Jingyi Lu, et al.
Journal of Orthopaedic Translation|May 25, 2026
Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III studyJiemei Gu, Aijun Chao, Yanan Huo, et al.
Journal of Orthopaedic Translation|November 16, 2022
Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III studyJiemei Gu, Hao Zhang, Qingyun Xue, et al.
Diabetologia|March 19, 2026
Correction: Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trialDalong Zhu, Jianhua Ma, Weimin Wang, et al.
Diabetologia|November 21, 2025
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trialDalong Zhu, Jianhua Ma, Weimin Wang, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Nature Communications|May 8, 2026
Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2)Weiping Jia, Fei Gao, Jingyi Lu, et al.
Journal of Orthopaedic Translation|May 25, 2026
Efficacy of once-weekly teriparatide versus alendronate in Chinese postmenopausal osteoporosis: a randomised, open-label, active-controlled, 48-week, multicentre phase III studyJiemei Gu, Aijun Chao, Yanan Huo, et al.
Journal of Orthopaedic Translation|November 16, 2022
Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III studyJiemei Gu, Hao Zhang, Qingyun Xue, et al.
Diabetologia|March 19, 2026
Correction: Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trialDalong Zhu, Jianhua Ma, Weimin Wang, et al.
Diabetologia|November 21, 2025
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trialDalong Zhu, Jianhua Ma, Weimin Wang, et al.
Pageof 8